Original Research Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma

被引：5

作者：

He, Wen-Zhuo ^{[1
]}

Huang, Yu-Hua ^{[2
]}

Hu, Wan-Ming ^{[2
]}

Wang, Fang ^{[3
]}

Xu, Yu-Xia ^{[4
]}

Yi, Jia-Hong ^{[1
]}

Xue, Ju ^{[1
]}

Yang, Yuan-Zhong ^{[2
]}

Chao, Xiao-Ying ^{[5
,6
]}

Lin, Han-Bin ^{[6
,7
,8
]}

Guo, Gui-Fang ^{[1
]}

Yun, Jing-Ping ^{[2
]}

Xia, Liang-Ping ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, VIP Reg,Canc Ctr, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Pathol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China

[4] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[5] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanning, Guangxi, Peoples R China

[6] Chinese Acad Sci, Zhongshan Inst Drug Discovery, SIMM, Zhongshan, Guangdong, Peoples R China

[7] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China

[8] SSIP Healthcare & Med Demonstrat Zone, Zhongshan 528400, Guangdong, Peoples R China

来源：

EUROPEAN JOURNAL OF CANCER | 2023年 / 194卷

基金：

中国国家自然科学基金;

关键词：

Epstein-Barr virus; Intrahepatic cholangiocarcinoma; Programmed cell death protein 1; Immunotherapy; MISMATCH-REPAIR; CLINICOPATHOLOGICAL FEATURES; SOLID TUMORS; EXPRESSION;

D O I：

10.1016/j.ejca.2023.113337

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Epstein-Barr virus-associated intrahepatic cholangiocarcinoma (EBVaICC) has a distinct genomic profile and increased CD3+ and CD8+ T cells infiltration. However, the efficacy of immunotherapy in EBVaICC remains largely unknown. This study aimed to assess the efficacy of programmed cell death protein 1 (PD-1) antibody therapy in EBVaICC. Methods: Patients with metastatic biliary tract cancer (BTC) diagnosed at Sun Yat-sen University Cancer Center from January 2016 to December 2021 were identified. In situ hybridisation was performed to detect EBV. Overall survival (OS) and progression-free survival (PFS) were measured. Results: A total of 698 patients with metastatic BTC were identified, of whom 39 (5.6%) had EBVaICC. Among the 136 patients who were not administered PD-1 antibody, the OS was similar between patients with EBVaICC and EBV-negative ICC (median OS 12.5 versus 9.5 months, respectively; P = 0.692). For the 205 patients who were administered PD-1 antibody, patients with EBVaICC had significantly longer OS than patients with EBV-negative ICC (median OS 24.9 versus 11.9 months, respectively; P = 0.004). Seventeen patients with EBVaICC were administered PD-1 antibody. Eight patients (47%) achieved a partial response, and 17 patients achieved disease control. The median PFS was 17.5 months. Conclusions: This study identified a clinically actionable subset of patients with EBVaICC with a promising response to the PD-1 antibody. (c) 2023 Elsevier Ltd. All rights reserved.

引用

页数：9